MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

INTRODUCTION: Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which con...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Sarah, Sherratt, Debbie, Hinsley, Samantha, Flanagan, Louise, Roberts, Sadie, Walker, Katrina, Hall, Andrew, Pratt, Guy, Messiou, Christina, Jenner, Matthew, Kaiser, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993167/
https://www.ncbi.nlm.nih.gov/pubmed/33762245
http://dx.doi.org/10.1136/bmjopen-2020-046225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993167/
https://www.ncbi.nlm.nih.gov/pubmed/33762245
http://dx.doi.org/10.1136/bmjopen-2020-046225

Ejemplares similares